We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aegerion Pharmaceuticals, Inc., in collaboration with Pfizer Inc and the University of Pennsylvania, have entered into a cross-license relationship covering a range of patents related to the use of microsomal triglyceride transfer protein (MTP) inhibitors.
Drug reviews that are supported by the pharmaceutical industry tend to be more biased and rate the drugs more favorably than independent reviews, a new study contends.
AnorMED Inc. ("AnorMED" or the "Company") announced that its Board of Directors has recommended that AnorMED shareholders accept and tender their shares to the offer by Millennium Pharmaceuticals, Inc., filed with applicable securities regulators and being mailed to shareholders, to purchase all of the outstanding common shares of AnorMED including all common shares issuable on the exercise of outstanding stock options, for US$12.00 per share in cash.
Shire plc said Friday that its collaborative partner New River Pharmaceuticals Inc. received an approvable letter from the U.S. Food and Drug Administration for NRP104 for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder.
Bristol-Myers Squibb Co. has added a black box warning to the label of its blood-thinner drug Coumadin for the risk of possible fatal bleeding, the Food and Drug Administration said Friday.
Deviations from current good manufacturing practices by chemical company Hawkins caused active pharmaceutical ingredients (APIs) to become contaminated when they were repackaged and relabeled, the FDA said in a warning letter to the company.
Delayed drug approvals have caused Altana Pharma to dismantle its marketing and sales organization in Florham Park, N.J. by the end of the year, the company announced Oct. 3.
A nanotechnology industry group is taking issue with a report commissioned by the Project on Emerging Nanotechnologies that asserts that the agency lacks both the legal and financial resources to regulate products containing nanomaterials, saying the agency in fact has "robust legal authority" to carry out the job.
Valentis, Inc. and Urigen N.A., Inc., a privately held specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications, announced the signing of a definitive merger agreement.